top of page
  • Corradin O, Sallari R, Hoang AT, Kassim BS, Ben Hutta G, Cuoto L, Quach BC, Lovrenert K, Hays C, Gryder BE, Iskhakova M, Cates H, Song Y, Bartels CF, Hancock DB, Mash DC, Johnson EO, Akbarian S, Scacheri PC. Convergence of case-specific epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. Molecular Psychiatry (2022). 

  • *Factor DC, *Barbeau AM, Allan K, Hu L, Madhavan M, Hoang AT, Hazel KEA, Hall PA, Nisraiyya S, Najm FJ, Miller TE, Nevin ZS, Karl RT, Lima BR, Song Y, Sibert, AG, Dhillon GK, Volsko C, Bartels CF, Adams DJ, Dutta R, Gallagher, MD, Phu W, Kozlenkov A, Dracheva S, Scacheri PC, Tesar PJ, Corradin O.  Cell type specific intralocus interactions reveal oligodendrocyte mechanisms in MS. Cell (2020).

    • *equal contribution

  • Lager AM, Corradin O, Cregg JM, Elitt MS, Shick HE, Clayton BLL, Allan KC, Olsen HE, Madhavan M, Tesar PJ. Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nature Communications (2018).



  • Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Bartels CF, Dhillon G, Bayles IM, Beard L, Myeroff L, Markowitz S, Scacheri PC. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications (2017).

  • Corradin O, Cohen AJ, Luppino JM, Bayles IM, Schumacher, FR and Scacheri PC. Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry. Nature Genetics (2016).

  • Budnick I, Hamburg-Shields E, Chen D, Torre E, Jarrell A, Akhtar-Zaidi B, Corradin O, Spitale RC, Scacheri PC, and Atit RP. Defining the identity of mouse embryonic dermal fibroblasts. Genesis. (2016).

  • Bailey S, Zhang X, Desai K, Aid M, Corradin O, Cowper Sal lari R, Akhtar-Zaidi B, Scacheri PC, Haibe-Kains B, and Lupien M. ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters. Nature Communications (2015).

  • Vucicevic D, Corradin O, Scacheri PC, Ørom UA. Long ncRNA expression associates with tissue-specific enhancers. Cell Cycle (2015).

  • Corradin O, Scacheri PC. Enhancer variants: evaluating functions in common disease. Genome Medicine. 6:85 Review. (2014).

  • Factor DC*, Corradin O*, Zentner GE, Saiakhova A, Song L, Chenoweth JG, McKay RD, Crawford GE, Scacheri PC, Tesar PJ: Epigenomic Comparison Reveals Activation of "Seed" Enhancers during Transition from Naive to Primed Pluripotency. Cell Stem Cell, 14:854-863. (2014).

    • *equal contribution

  • Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Sal Lari R, Lupien M, Markowitz S, Scacheri PC. 2014. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Research 24(1): 1-13. (2014).

  • Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, Willis J, Moore JH, Tesar PJ, Laframboise T, Markowitz S, Lupien M, Scacheri PC. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336, 736-9 (2012).

bottom of page